AIM: To assess reasons that prevent Alzheimer's disease (AD) patients from being included in clinical trials. METHODS: In 2009, we reviewed the Lille Memory Clinic's case database to identify patients suitable for inclusion in four AD clinical trials. An initial selection was made on the basis of four criteria: (i) a diagnosis of AD (with or without white matter lesions [WML]), (ii) age, (iii) mini mental state examination (MMSE) score and (iv) symptomatic treatment of AD (cholinesterase inhibitors/memantine). Next, data on patients fulfilling these criteria were reviewed against all the inclusion/exclusion criteria for four clinical trials performed in 2009 at the Memory Clinic. Reasons for non-inclusion were analyzed. RESULTS: Two hundred and five patients were selected according to the four initial criteria. Reasons for subsequently not including some of patients in clinical trials were abnormalities on MRI (56.9%, 88.9% of which were WML), unauthorized medication (37.3%), the lack of a study partner/informant (37.1%), the presence of a non-authorized disease (24.4%), contraindication to MRI (9%), a change in diagnosis over time (3.9%), visual/auditory impairments (2.9%), alcohol abuse (2%) and an insufficient educational level (1%). CONCLUSION: A high proportion of AD patients presented with vascular abnormalities on MRI. This was not unexpected, since the patients were selected from the database and, as shown in epidemiologic studies, cerebrovascular diseases are frequently associated with AD. The presence of a study partner is essential for enabling a patient to participate in clinical trials because of the need to record reliably primary and secondary outcomes.
AIM: To assess reasons that prevent Alzheimer's disease (AD) patients from being included in clinical trials. METHODS: In 2009, we reviewed the Lille Memory Clinic's case database to identify patients suitable for inclusion in four AD clinical trials. An initial selection was made on the basis of four criteria: (i) a diagnosis of AD (with or without white matter lesions [WML]), (ii) age, (iii) mini mental state examination (MMSE) score and (iv) symptomatic treatment of AD (cholinesterase inhibitors/memantine). Next, data on patients fulfilling these criteria were reviewed against all the inclusion/exclusion criteria for four clinical trials performed in 2009 at the Memory Clinic. Reasons for non-inclusion were analyzed. RESULTS: Two hundred and five patients were selected according to the four initial criteria. Reasons for subsequently not including some of patients in clinical trials were abnormalities on MRI (56.9%, 88.9% of which were WML), unauthorized medication (37.3%), the lack of a study partner/informant (37.1%), the presence of a non-authorized disease (24.4%), contraindication to MRI (9%), a change in diagnosis over time (3.9%), visual/auditory impairments (2.9%), alcohol abuse (2%) and an insufficient educational level (1%). CONCLUSION: A high proportion of ADpatients presented with vascular abnormalities on MRI. This was not unexpected, since the patients were selected from the database and, as shown in epidemiologic studies, cerebrovascular diseases are frequently associated with AD. The presence of a study partner is essential for enabling a patient to participate in clinical trials because of the need to record reliably primary and secondary outcomes.
Authors: Cleusa P Ferri; Martin Prince; Carol Brayne; Henry Brodaty; Laura Fratiglioni; Mary Ganguli; Kathleen Hall; Kazuo Hasegawa; Hugh Hendrie; Yueqin Huang; Anthony Jorm; Colin Mathers; Paulo R Menezes; Elizabeth Rimmer; Marcia Scazufca Journal: Lancet Date: 2005-12-17 Impact factor: 79.321
Authors: L O Wahlund; F Barkhof; F Fazekas; L Bronge; M Augustin; M Sjögren; A Wallin; H Ader; D Leys; L Pantoni; F Pasquier; T Erkinjuntti; P Scheltens Journal: Stroke Date: 2001-06 Impact factor: 7.914
Authors: B Vellas; H Hampel; M E Rougé-Bugat; M Grundman; S Andrieu; S Abu-Shakra; R Bateman; R Berman; R Black; M Carrillo; M Donohue; M Mintun; J Morris; R Petersen; R G Thomas; J Suhy; L Schneider; L Seely; P Tariot; J Touchon; M Weiner; C Sampaio; P Aisen Journal: J Nutr Health Aging Date: 2012-04 Impact factor: 4.075
Authors: Miriam T Ashford; Rema Raman; Garrett Miller; Michael C Donohue; Ozioma C Okonkwo; Monica Rivera Mindt; Rachel L Nosheny; Godfrey A Coker; Ronald C Petersen; Paul S Aisen; Michael W Weiner Journal: Alzheimers Dement Date: 2022-02-25 Impact factor: 16.655
Authors: Klaus Hager; Alan S Baseman; Jeffrey S Nye; H Robert Brashear; John Han; Mary Sano; Bonnie Davis; Henry M Richards Journal: Alzheimers Res Ther Date: 2016-11-15 Impact factor: 6.982
Authors: Rachel L Nosheny; Monica R Camacho; Philip S Insel; Derek Flenniken; Juliet Fockler; Diana Truran; Shannon Finley; Aaron Ulbricht; Paul Maruff; Kristine Yaffe; R Scott Mackin; Michael W Weiner Journal: Alzheimers Dement (N Y) Date: 2018-10-15